Use of pancreatic colipase antagonists to impede weight gain
CA 2484088 A1 · Owner: Promega Corporation · Inventors: Kink, John A.; Stafford, Douglas C.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A therapy for humans or other animals is described using one or more antagonists to colipase so as to interfere with macromolecular nutrient digestion. In one embodiment, the present invention describes the use of antibodies that can be administered by a variety of routes including orally, over a treatment period in a manner that promotes weight loss or impedes weight gain.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 24, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 24, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 24, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.